CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing ; volume:7 ; number:1 ; day:13 ; month:8 ; year:2024 ; pages:1-15 ; date:12.2024
Communications biology ; 7, Heft 1 (13.8.2024), 1-15, 12.2024
- Creator
-
Liao, Chen-Yi
Engelberts, Patrick
Ioan-Facsinay, Andreea
Klip, Janna Eleonora
Schmidt, Thomas
Ruijtenbeek, Rob
Danen, Erik H. J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-024-06682-9
- URN
-
urn:nbn:de:101:1-2411010804242.545900828521
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liao, Chen-Yi
- Engelberts, Patrick
- Ioan-Facsinay, Andreea
- Klip, Janna Eleonora
- Schmidt, Thomas
- Ruijtenbeek, Rob
- Danen, Erik H. J.
- SpringerLink (Online service)
Other Objects (12)
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
Anti-tumor activity, pharmacology and toxicology of EpCAM-, CD3-bispecific single-chain antibodies
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies